Article Text
Statistics from Altmetric.com
Marsh and colleagues1 raise the spectre of a possible association between the use of sildenafil and the development of retinopathy of prematurity (ROP) in a baby of 26 weeks gestation with pulmonary hypertension. We are concerned that this report offers no real evidence for its claims and that a potentially lifesaving agent is being unfairly maligned.
The report describes the use of intravenous sildenafil of unspecified dose for 16 days in a 525 g preterm infant with a very difficult intensive care course. The …
Footnotes
-
Conflict of interest: The authors have acted in an independent consultant capacity (CMP, AJP, ARF) and are in receipt of financial support in the form of a research grant (CMP, AJP) from the manufacturers of sildenafil, Pfizer Ltd.